已发表论文

通过布地奈德/格隆溴铵/福莫特罗富马酸酯成功治疗连续性严重哮喘并存 COVID-19

 

Authors Liang Y, Chen M, Tan C, Tu C, Zheng X, Liu J

Received 11 November 2020

Accepted for publication 8 January 2021

Published 4 February 2021 Volume 2021:14 Pages 357—359

DOI https://doi.org/10.2147/IJGM.S291695

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Scott Fraser

Abstract: Awareness of the management of coronavirus disease 2019 (COVID-19) and airway diseases can effectively help clinical physician during the coronavirus pandemic. Herein, we elucidated a COVID-19 case coexisting with severe asthma. Budesonide/glycopyrrolate/formoterol fumarate (BGF) was used as sequential medicine to systemic glucocorticoids for his persisted symptoms related to bronchospasms. Our case suggests patients with long-term airway diseases like asthma probably attribute their symptoms to COVID-19 instead of primary diseases, which make it more difficult in the symptom control. BGF is able to be an effective and convenient choice as sequential medicine to systemic glucocorticoids in some refractory asthmatic patients complicated with COVID-19.
Keywords: coronavirus disease 2019, asthma, budesonide/glycopyrrolate/formoterol fumarate, sequential treatment